Navigation Links
PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
Date:4/30/2013

tability improvement initiatives tracked according to plan, (especially in the Clinical Research Services business), and we delivered strong growth in earnings per share.  We continue to be excited about the Liquent acquisition, and the integration has proceeded smoothly and as expected.  We also welcome our new colleagues from the HERON Group, an acquisition that we announced today, and which bolsters our commercialization capabilities."

He continued, "Looking into the future, I am confident about the prospects for PAREXEL.  We believe the overall market for our services remains healthy, and our differentiated product and service offerings continue to be well received by clients.  The investments that we have made over the years are paying off, and I believe that we have the talent, resources, and infrastructure in place to continue to succeed in the evolving CRO marketplace.  We remain committed to our goal of achieving Fiscal Year 2013 earnings per share growth in the range of 44% to 48%, driven by continued revenue growth, effective cost management, margin expansion, and the previously announced stock buyback."

The Company issued forward-looking guidance for the fourth quarter of Fiscal Year 2013 (ending June 30, 2013), for Fiscal Year 2013, and for Calendar Year 2013 as described in the text and chart below.  The guidance takes into account the acquisition of the HERON Group Limited ("HERON"), recent exchange rates, revised tax rates, the estimated impact of the stock buyback program, and the Company's updated overall outlook.  For the fourth quarter of Fiscal Year 2013, HERON is expected to contribute between $3.0 and $4.0 million in service revenue, and to contribute between $11.0 and $14.0 million for Calendar Year 2013.  The impact of the HERON acquisition is expected to be neutral to earnings for the remainder of Calendar Year 2013.  Excluding the amortization of intangibles and certain other costs
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
5. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
6. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
7. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
8. PAREXEL International to Present at Morningstar Conference
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
10. UV Flu Technologies Expands Its International Footprint
11. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ) ... with Novartis Pharma AG to acquire worldwide rights to ... development.  This agreement is conditional on the closing of transactions ... 2014, which are expected to close in the first ...
(Date:1/22/2015)... Bedford, NH (PRWEB) January 22, 2015 ... offers a table top laboratory homogenizer, the PandaPLUS 2000, ... nanoparticles, nanodispersions, nanoemulsions , and cell disruption . ... processing dairy products, fruit juices, liquid food, food additives ...
(Date:1/22/2015)... January 22, 2015 Crystal Diagnostics (CDx) Xpress ... it has received AOAC-PTM Certifications for the six non-O157 Shiga ... O145; collectively referred to as STEC or the “Big-6”) as ... forming unit (cfu) per 325 g of raw ground beef ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... Pivotal Study in, Rituximab Refractory Follicular Non-Hodgkin,s lymphoma ... Number ... Genmab A/S (OMX:,GEN) announced today it has amended the design ... follicular,non-Hodgkin,s lymphoma (NHL) to a single arm trial that will ...
... May Help Increase Appropriate Early Use in Acute Coronary Syndrome ... ... 27 ,Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb,Company (NYSE: ... approved a supplemental new drug application,(sNDA) for a 300mg tablet of the ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... commercializing proprietary product candidates for the treatment,of ... data from,preclinical studies of ANX-514 (docetaxel emulsion) ... Cancer Research (AACR), National Cancer,Institute (NCI) and ...
Cached Biology Technology:Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 2Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 2FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 4FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 5ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 2ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 4
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics Agency ... detect and prevent counterfeit microcircuits from entering into its ... an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The ... increasing their reliability throughout the supply chain. The new ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced ... 2015-2019" report to their offering. ... a technology used for the identification of individuals. Facial ... person such as nose, jaw edges, mouth, and the ...
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you desperately need ... password, site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure security company, ... to the frustration that comes with usernames, passwords and PINs – ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Adults undergoing bariatric surgery who are more physically ... and to have recently received medication or counseling ... counterparts, according to new research led by the ... "Typically, clinical professionals manage their patients, ...
... assortment of amphibian species living in a pond, the more ... a parasitic infection that can cause severe deformities, including the ... the University of Colorado Boulder. The findings, published ... idea that greater biodiversity in larger-scale ecosystems, such as forests ...
... Neil Hunter,s laboratory in the UC Davis College of Biological ... sexual reproduction shuffles genes while making sure sperm and eggs ... sexual reproduction is that a fertilized egg gets half its ... one partner in each pair of chromosomes. We humans have ...
Cached Biology News:Physical activity linked to lower rates of depression in bariatric surgery patients 2Physical activity linked to lower rates of depression in bariatric surgery patients 3CU-Boulder amphibian study shows how biodiversity can protect against disease 2CU-Boulder amphibian study shows how biodiversity can protect against disease 3CU-Boulder amphibian study shows how biodiversity can protect against disease 4Clues to chromosome crossovers 2
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... clear, APET plastic tray. Ideal for staining ... trays used for multipurposes. Pour spouts in ... marker or label may be used for ... on rockers or shakers for staining several ...
ID clarifier: non-treated with lid...
... Staccato Series of systems provide fast and reliable scalable ... drug development laboratories. Staccato systems are available in three ... Systems Series. ... All Staccato ...
Biology Products: